PMID- 23489256
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140303
LR  - 20200929
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 43
IP  - 11
DP  - 2013 Nov
TI  - Efficacy and safety in sitagliptin therapy for diabetes complicated by 
      non-alcoholic fatty liver disease.
PG  - 1163-8
LID - 10.1111/hepr.12077 [doi]
AB  - AIM: The aim of this case-control study was to assess the efficacy and safety of 
      dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus 
      (T2DM) with non-alcoholic fatty liver disease (NAFLD). METHODS: Twenty NAFLD 
      patients with T2DM treated by sitagliptin were retrospectively enrolled as the 
      sitagliptin group. These patients were given sitagliptin between January 2010 and 
      July 2011. Another 20 NAFLD patients with T2DM treated only with diet and 
      exercise for 48 weeks were selected as the control group. Serum levels of fasting 
      plasma glucose (FPG), hemoglobin A1C (HbA1c), aspartate aminotransferase (AST) 
      and alanine aminotransferase (ALT) were measured before and 12, 24, 36 and 
      48 weeks after the initiation of treatment. RESULTS: In the sitagliptin group, 
      average HbA1c levels decreased approximately 0.7% at 48 weeks after the 
      initiation of sitagliptin. Next, average FPG levels decreased approximately 
      15 mg/dL at 48 weeks after the initiation of sitagliptin. The serum levels of 
      HbA1c and FPG in the sitagliptin group decreased with statistical significance 
      compared to those in the control group (P < 0.05). All the patients could take 
      sitagliptin of 50 mg/day without reduction necessitated by sitagliptin-related 
      side-effects. There were no significant changes of average AST and ALT levels 
      during follow up of 48 weeks in both sitagliptin and control groups. CONCLUSION: 
      Our results indicate sitagliptin is effective and safe for the treatment of T2DM 
      complicated with NAFLD.
CI  - (c) 2013 The Japan Society of Hepatology.
FAU - Arase, Yasuji
AU  - Arase Y
AD  - Department of Hepatology and Okinaka Memorial Institute for Medical Research, 
      Toranomon Hospital, Tokyo, Japan; Department of Health Management Center, 
      Toranomon Hospital, Tokyo, Japan.
FAU - Kawamura, Yusuke
AU  - Kawamura Y
FAU - Seko, Yuya
AU  - Seko Y
FAU - Kobayashi, Mariko
AU  - Kobayashi M
FAU - Suzuki, Fumitaka
AU  - Suzuki F
FAU - Suzuki, Yoshiyuki
AU  - Suzuki Y
FAU - Akuta, Norio
AU  - Akuta N
FAU - Kobayashi, Masahiro
AU  - Kobayashi M
FAU - Sezaki, Hitomi
AU  - Sezaki H
FAU - Saito, Satoshi
AU  - Saito S
FAU - Hosaka, Tetsuya
AU  - Hosaka T
FAU - Ikeda, Kenji
AU  - Ikeda K
FAU - Kumada, Hiromitsu
AU  - Kumada H
FAU - Ohmoto-Sekine, Yuki
AU  - Ohmoto-Sekine Y
FAU - Hsieh, Shiun Dong
AU  - Hsieh SD
FAU - Amakawa, Kazuhisa
AU  - Amakawa K
FAU - Ogawa, Kyoko
AU  - Ogawa K
FAU - Matsumoto, Naoki
AU  - Matsumoto N
FAU - Iwao, Akiko
AU  - Iwao A
FAU - Tsuji, Hiroshi
AU  - Tsuji H
FAU - Hara, Shigeko
AU  - Hara S
FAU - Mori, Yasumichi
AU  - Mori Y
FAU - Okubo, Minoru
AU  - Okubo M
FAU - Sone, Hirohito
AU  - Sone H
FAU - Kobayashi, Tetsuro
AU  - Kobayashi T
LA  - eng
PT  - Journal Article
DEP - 20130312
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - non-alcoholic fatty liver disease
OT  - sitagliptin
OT  - type 2 diabetes mellitus
EDAT- 2013/03/16 06:00
MHDA- 2013/03/16 06:01
CRDT- 2013/03/16 06:00
PHST- 2012/11/09 00:00 [received]
PHST- 2012/12/25 00:00 [revised]
PHST- 2013/01/20 00:00 [accepted]
PHST- 2013/03/16 06:00 [entrez]
PHST- 2013/03/16 06:00 [pubmed]
PHST- 2013/03/16 06:01 [medline]
AID - 10.1111/hepr.12077 [doi]
PST - ppublish
SO  - Hepatol Res. 2013 Nov;43(11):1163-8. doi: 10.1111/hepr.12077. Epub 2013 Mar 12.